A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2004
12/30/2004	US20040266696 activating neovascularization by administering heptapeptides having replacements in the amino acid sequence; antiischemic agents; regeneration and maintenance of artificial bones
12/30/2004	US20040266694 Angiogenesis inhibitor induced by vascular endothelial growth factor
12/30/2004	US20040266687 Antiproliferative agents; antiinflammatory agents; angiogenesis inhibitors; anticancer agents
12/30/2004	US20040266686 Administering endothelial growth factor antagonist; wound healing agents
12/30/2004	US20040266682 administering gastrin/(cholecystokinin (CCK) receptor ligand and a factor for complementing gastrin for islet neogenesis therapy; sustained release; for expanding a functional beta cell mass of pancreatic islet transplants; reduces amount of stem cells necessary for treatment; kits
12/30/2004	US20040266676 Preventives/remedies for proliferative organ diseases chronic arthritic diseases. hypertrophic scar or keloid
12/30/2004	US20040266675 Transgenic aniomal nmodels; screening; administering peptide
12/30/2004	US20040266661 Method for reducing hypertension and heart failure
12/30/2004	US20040265979 Novel macrophage foam cell formation inhibitor fka-25 and process for producing the same
12/30/2004	US20040265971 Cytokine for use in stem cell propagation and treatment ot cardiovascular, bone, nervous system and inflammatory disorders
12/30/2004	US20040265958 that hydrolyzes fatty amides such as cis-9,10-octadecenoamide to neutralize the soporific activity of the fatty amides; enzyme inhibitors for use in treating sleep disorders
12/30/2004	US20040265913 Tumor necrosis factors (TNF); humanized/chimeric monoclonal antibodies; fab fragments; hybridomas, host cells, Chinese Hamster Ovary cells
12/30/2004	US20040265891 use in diagnosis and treatment of cancer, neurodegenerative, or immune disorders; antibodies for immunoassays; drug screening
12/30/2004	US20040265890 a polypeptide of given amino acid sequence; use as drug target for gastrointestinal disorders; fusion proteins; diagnosis
12/30/2004	US20040265885 Peptide nucleic acid (PNA) derivatives which carry one or more phosphoryl radicals at the N terminus of the PNA backbone; can be purified using efficient methods such as chromatography or electrophoresis; use as pharmaceuticals and diagnostic agents
12/30/2004	US20040265856 5' portion of an intestinal lactase-phlorizine hydrolase (LPH) gene; point mutations; solid phase synthesis; immunoassay; vectors; primers; host cells; antibodies; kits; gene therapy
12/30/2004	US20040265839 Gene knockout; gene overexpression; liposomes; fusion proteins; immunoglobulins; FC fragments; glutathione S-transferase (GST) polypeptides
12/30/2004	US20040265837 As well as Paget's disease, neurological/neuromuscular diseases, nerve diseases, and/or psychotropic diseases; chloride channel modulators
12/30/2004	US20040265787 Immortalized human keratinocyte cell line
12/30/2004	US20040265399 plant extracts used for prevention or treatment of lesions caused by estrogen deficiency
12/30/2004	US20040265382 Methylsulfonylphenyl or phenylsulfonamide derivatives having ring selected from cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine; celecoxib and rofecoxib; administered for pain; oral drug delivery
12/30/2004	US20040265369 Compounds that inhibit caspase activity for treating glaucoma
12/30/2004	US20040265362 Adhesive, skin and/or nail permeation enhancer; drug contained in contact layer; and binders, crosslinking agents, softeners, solvents, fillers and/or antioxidants; occlusive backing; fungal infection treatment of onychomycosis
12/30/2004	US20040265357 Combination of liponic acid and glutamine in food and pharmaceutical products
12/30/2004	US20040265319 Geranyl-geranyl acetone as an active ingredient for treating influenza virus infection
12/30/2004	US20040265311 Methods for diagnosing and treating hemostatic disorders by modulating P-selectin activity
12/30/2004	US20040265307 Anti-IGF-I receptor antibody
12/30/2004	US20040265303 Anti-CCR2 antibodies and methods of use therefor
12/30/2004	US20040265300 Targeting cancer cell; induction or prevention of apoptosis in eukaryotic cells; a fusion peptide contains a viral apoptotic peptide and an antibody fragment; recombinant host cell comprising the vector, encoding chimeric polypeptide; bioassay monitoring apoptosis activity; drug target
12/30/2004	US20040265284 Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains
12/30/2004	US20040265283 Hepatocyte growth factor gene as an active therapeutic agent; biodrugs; Parkinson's disease, Alzheimer's disease, spinal cord injury, diabetic peripheral neuritis, and ischemic cerebrovascular disorders (cerebral infarction, cerebral haemorrhage)
12/30/2004	US20040265228 biomarkers for medicinal radioimaging such as Positron Emission Tomography; 4-Anilinoquinazolines
12/29/2004	WO2004113523A1 Granzyme b/golgin-160 interaction inhibitor
12/29/2004	WO2004113378A2 Control of lactation and peptides therefore
12/29/2004	WO2004113359A1 Pyrazole derivative, drug composition containing the same and production intermediate therefor
12/29/2004	WO2004113345A1 Fused pyrrole compound and medicinal use thereof
12/29/2004	WO2004113300A1 Novel tricyclic heterocycle compound
12/29/2004	WO2004112817A1 Extract from plant of japanese parsley family and process for producing the same
12/29/2004	WO2004112815A1 Melanogenesis promoter and melanogenesis promoter composition
12/29/2004	WO2004112809A1 Composition for lowering serum uric acid level
12/29/2004	WO2004112803A1 Methods of managing the symptoms of premenstrual syndrome
12/29/2004	WO2004112762A2 Pharmaceutical formulations of amyloid inhibiting compounds
12/29/2004	WO2004112510A1 Movement physiology improver
12/29/2004	WO2004015072A3 Mrbs as modifiers of the rb pathway and methods of use
12/29/2004	WO2004009091A8 Purine derivatives as liver x receptor agonists
12/29/2004	WO2004002940A8 Inhibitors of hcv ns5b polymerase
12/29/2004	WO2004001014A3 Osteopontin, oligodendrocytes and myelination
12/29/2004	WO2003103671A8 Basic non-peptide bradykinin antagonists and pharmaceutical compositions therefrom
12/29/2004	WO2003045984A3 Fibronectin and fibrinogen biopolymer markers indicative of insulin resistance
12/29/2004	WO2003015797A8 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
12/29/2004	WO2002043648A3 Compounds active at the glucocorticoid receptor ii
12/29/2004	EP1492019A1 Method of forming molecule function network
12/29/2004	EP1491632A2 Anti-alphavbeta3 humanized monoclonal antibodies
12/29/2004	EP1491553A1 Peptides for the treatment of cancer associated with the human papilloma virus (hpv) and other epithelial tumours
12/29/2004	EP1491551A1 Estrone derivative and process for producing the same
12/29/2004	EP1491541A1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1491540A1 Pyridazinone aldose reductase inhibitors
12/29/2004	EP1491539A1 1-n-aminobenzimidazole derivatives
12/29/2004	EP1491538A1 Anti-mitotic agents which inhibit tubulin polymerization
12/29/2004	EP1491537A1 Hydroxymorpholinone derivative and medicinal use thereof
12/29/2004	EP1491534A1 Novel hairpin polyamide
12/29/2004	EP1491533A2 Quinoline-and naphthalenecarboxamides, pharmaceutical compositions thereof and their use as calpain inhibitors
12/29/2004	EP1491531A1 (1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
12/29/2004	EP1491236A1 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
12/29/2004	EP1491211A1 Remedy for glioblastoma
12/29/2004	EP1491208A1 Stabilized liquid polypeptide-containing pharmaceutical compositions
12/29/2004	EP1491207A1 Novel screening method
12/29/2004	EP1491205A1 Remedy for hypermyotonia
12/29/2004	EP1491198A1 use of vitamin d derivatives to enhance efficacy of cytotoxic agents
12/29/2004	EP1491194A1 Vdac regulator
12/29/2004	EP1491193A1 Therapeutic combinations comprising amlodipine and atorvastatin
12/29/2004	EP1491192A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
12/29/2004	EP1491190A1 Decomposition inhibitor for extracellular matrix of cartilage
12/29/2004	EP1491187A1 Preventive or therapeutic agent for kidney disease
12/29/2004	EP1491183A2 Use of a plant extract of the Rosaceae family
12/29/2004	EP1491093A2 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
12/29/2004	EP1490686A2 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
12/29/2004	EP1490505A1 Tryptophan aminotransferase, indole-3-pyruvate decarboxylase and indole-3-acetaldehyde oxidase as novel targets for herbicides
12/29/2004	EP1490479A1 Dedifferentiated, programmable stem cells having a monocytic origin and the production and use thereof
12/29/2004	EP1490405A2 ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
12/29/2004	EP1490401A1 Vegf peptides and their use
12/29/2004	EP1490391A1 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring substituted with a long chain at the 11beta position
12/29/2004	EP1490386A2 Novel polypeptides and nucleic acids encoding the same
12/29/2004	EP1490373A1 Inhibitors of nucleoside phosphorylases and nucleosidases
12/29/2004	EP1490367A1 Imidazopyridine derivatives as kinase inhibitors
12/29/2004	EP1490365A1 Azaindoles as inhibitors of c-jun n-terminal kinases
12/29/2004	EP1490364A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
12/29/2004	EP1490363A1 Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
12/29/2004	EP1490357A1 Stable hydrate of a muscarinic receptor antagonist
12/29/2004	EP1490356A1 (3z)-3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
12/29/2004	EP1490352A1 Synthesis of piperidine and piperazine compounds as ccr5 antagonists
12/29/2004	EP1490350A1 Pyranon and pyrandion inhibitors of hepatitis c virus rna-dependent rna polymerase
12/29/2004	EP1490341A1 Novel adamantane derivatives
12/29/2004	EP1490339A1 Novel chalcone derivatives and uses thereof
12/29/2004	EP1490338A1 Use of an alfa2-adrenoreceptor antagonist for cns-related diseases
12/29/2004	EP1490336A1 Piperidine or 8-aza-bicyclo(3.2.1)oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially ccr5)
12/29/2004	EP1490335A2 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/29/2004	EP1490334A1 Phthalimido derivatives as inhibitors of monoamine oxidase b
12/29/2004	EP1490328A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation
12/29/2004	EP1490324A2 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors

1 ... 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 ... 1564